Investors

Press Releases

Press Releases

Nov 03, 2022

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

Nov 03, 2022

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

Oct 20, 2022

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

Oct 13, 2022

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Sep 15, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

Aug 29, 2022

Kymera Therapeutics to Participate in Upcoming September Conferences

Aug 19, 2022

Kymera Announces $150 Million Private Placement Equity Financing

Aug 09, 2022

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

Jul 27, 2022

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

Jul 08, 2022

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

Investor Contact

Bruce Jacobs, CFA, MBA
Chief Financial Officer
investors@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+ 1 339.970.2843

Media Contact

Todd Cooper
Sr. Vice President, Corporate Affairs
media@kymeratx.com

Sign Up for Email Alerts